SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Concerns about slowing consumer spending and weakening restaurant traffic are weighing on Wingstop, with traders also pointing to declining same-store sales and broader weakness across restaurant stocks. The sharp selloff has split the community between those viewing the shares as oversold and a potential value opportunity and those expecting further declines amid persistent business and valuation concerns.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas breakout to fresh highs and relative strength are drawing attention as traders position around its upcoming earnings report. Bulls point to resilient payment activity and momentum, while skeptics say the stock looks overbought or fully valued and could pull back.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Cloroxs weaker fiscal outlook, including expected declines in sales and earnings amid margin pressure, is driving the selloff despite a quarterly earnings beat. Traders are split between criticizing management and questioning the dividends sustainability, while value-focused investors see the drop as a buying opportunity in a defensive, dividend-paying company.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is drawing attention after a breakout amid strength in cybersecurity stocks, with traders cheering renewed highs and pointing to demand for cyber resilience as AI adoption expands. Others remain skeptical, citing the companys relative performance versus peers, valuation, and managements conservative guidance.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is drawing attention amid a cybersecurity-sector rally tied to concerns that AI is creating new security risks and demand for identity protection, including controls for AI agents. Traders are celebrating the breakout and momentum, while others argue the valuation has run too far and expect a pullback.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Discussion centers on Digital Turbines recent earnings momentum and growth prospects in mobile advertising, app distribution, and AI-agent delivery to devices. Bulls see a durable growth story, while skeptics point to the stocks pullback after earnings, low trading volume, debt and dilution concerns, and uncertainty ahead of the next report.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is drawing attention after rebounding from a recent selloff, with traders noting buyers defending support and bullish call activity. The debate remains split between hopes that the bounce can continue and concerns about a failed breakout, high valuation, and continued volatility.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

IGV is testing a long-standing resistance area, with traders divided between a breakout that would extend softwares relative strength and a rejection that could favor shorts. The wider debate centers on rotation between software and semiconductors, and whether AI will enhance established software platforms or disrupt SaaS businesses.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Schrdingers Tectora spinout, which advances two early-stage drug programs while preserving potential equity, milestone, and royalty upside, is a key focus of the bullish discussion around the stocks rally. Traders are split between optimism about AI-enabled drug discovery and concerns about overbought conditions; buyout speculation remains unconfirmed.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnsons quarterly results are drawing attention: adjusted performance and raised full-year guidance were outweighed in the share reaction by slower MedTech growth and a steep reported earnings decline tied partly to one-time charges. Traders are debating whether the selloff is overdone given pharmaceutical growth or reflects concern about weaker device momentum; speculation about a potential Sellas acquisition remains unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Equity

Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.


HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62  

TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.


CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs 

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.


ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies

AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies PR Newswire BETHESDA, Md...

ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat

Enveric stated during after-market hours on Thursday that it has entered into definitive agreements for the purchase and sale of 2.2 million shares of its common stock at a purchase price of $2.25.

ENVB Stock Dips After-Hours On Widening Q4 Loss Despite Study Progress On Psychiatry Drug

For the fourth quarter of 2025, the company reported net loss attributable of $4 million, higher than the loss of $3.2 billion reported for the corresponding quarter of 2024.


Advisorshares Trust - AdvisorShares Psychedelics ETF

Bullish Sentiment

<ul class="summary-bullets"><li>According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’</li><li>Investors are now awaiting data from the late-stage APPROACH study of HLP003.&nbsp;</li><li>If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration (FDA) seeking approval in 2028.</li></ul>Shares of Helus Pharma (HELP) opened on Friday at $15.15 and printed a new 52-week high before reversing gains after Barclays initiated coverage with an Overweight rating and a $35 price target ahead of upcoming trial results for its psychedelic drug.By midday, the stock was trading near $12.50, down about 11%, after touching a session low around $12.10.<h2 class="st-heading-2">Wall Street Takeaway</h2>Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.Barclays is not far off consensus. According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’ The 12-month average price target on the stock is $41.40, implying a potential upside of about 195%.<h2 class="st-heading-2">Near-Term Catalysts</h2>Helus develops novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways linked to neuroplasticity—for mental health conditions, mainly depression and anxiety.Investors are now awaiting data from the late-stage APPROACH study of HLP003 expected in the fourth quarter. The deuterated psilocin (the active form of psilocybin or the compound in magic mushrooms) drug is being tested as an add-on treatment for major depression and has FDA Breakthrough Therapy status. Enrollment finished in July.A second Phase 3 trial, EMBRACE, plus a long-term extension study, come after that readout. If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration seeking approval in 2028. HLP004, a deuterated DMT (a short-acting psychedelic) candidate for anxiety, remains earlier-stage after a mid-stage signal-finding study.Helus closed a $50 million offering in late June to fund the late-stage work. Michael Halstead took the helm of the company in early August. Further, in mid-September, Executive Chair Eric So and Chief Growth Officer Paul Glavine each bought 100,000 shares on the open market, purchases of roughly $1.2 million apiece.<h2 class="st-heading-2">How Did HELP Retail Traders React?</h2>On Stocktwits, retail sentiment around HELP stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user said that they added more shares today in light of the selloff.<stembedurl>https://stocktwits.com/GeorgeJetson17/message/664597609</stembedurl>Another reiterated confidence in the impact of psychedelic drugs on mental health.<stembedurl>https://stocktwits.com/Sibtsen/message/664590549</stembedurl><a href="https://stocktwits.com/symbol/HELP">HELP stock</a> has gained 53% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/len-arry-stocks-hit-new-lows-as-price-target-cuts-pile-up-what-s-driving-the-selloff/cZtHP4CRBEI">LEN, ARRY Stocks Hit New Lows As Price Target Cuts Pile Up — What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’Investors are now awaiting data from the late-stage APPROACH study of HLP003. If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration (FDA)

Helus Pharma Inc.

AdvisorShares Psychedelics ETF

Invesco NASDAQ Future Gen 200 ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

PSIL AdvisorShares Psychedelics ETF

Fundamentals

Latest PSIL News